Progress in the Development of Effective Vaccines to Prevent Selected Gram-Positive Bacterial Infections

Infections caused by virulent Gram-positive bacteria, such as Staphylococcus aureus, group B streptococci and group A streptococci, remain significant causes of morbidity and mortality despite progress in antimicrobial therapy. Despite significant advances in the understanding of the pathogenesis of infection caused by these organisms, there are only limited strategies to prevent infection. In this article, we review efforts to develop safe and effective vaccines that would prevent infections caused by these 3 pathogens.

[1]  John D. Rose,et al.  Prevalence of rheumatic heart disease in children and young adults in Nicaragua. , 2010, The American journal of cardiology.

[2]  J. Carapetis,et al.  Group A streptococcal vaccines: facts versus fantasy , 2009, Current opinion in infectious diseases.

[3]  L. Guilherme,et al.  A vaccine against S. pyogenes: design and experimental immune response. , 2009, Methods.

[4]  J. Carapetis,et al.  Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. , 2009, The Lancet. Infectious diseases.

[5]  G. Grandi,et al.  BibA induces opsonizing antibodies conferring in vivo protection against group B Streptococcus. , 2009, The Journal of infectious diseases.

[6]  R. Tanz,et al.  Seven-year surveillance of north american pediatric group a streptococcal pharyngitis isolates. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Carapetis,et al.  emm and C-Repeat Region Molecular Typing of Beta-Hemolytic Streptococci in a Tropical Country: Implications for Vaccine Development , 2009, Journal of Clinical Microbiology.

[8]  K. Jansen,et al.  Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. , 2009, Vaccine.

[9]  D. Kaufman,et al.  Antistaphylococcal immunoglobulins to prevent staphylococcal infection in very low birth weight infants. , 2009, Cochrane Database of Systematic Reviews.

[10]  Jean C. Lee,et al.  Staphylococcal vaccines and immunotherapies. , 2009, Infectious disease clinics of North America.

[11]  J. Musser,et al.  Sequence variation in group A Streptococcus pili and association of pilus backbone types with lancefield T serotypes. , 2008, The Journal of infectious diseases.

[12]  W. Schaffner,et al.  Revisiting the Need for Vaccine Prevention of Late-Onset Neonatal Group B Streptococcal Disease: A Multistate, Population-Based Analysis , 2008, The Pediatric infectious disease journal.

[13]  G. Yarranton,et al.  Antibodies for the treatment of bacterial infections: current experience and future prospects. , 2008, Current opinion in biotechnology.

[14]  M. Edwards Group B streptococcal conjugate vaccine: A timely concept for which the time has come , 2008, Human vaccines.

[15]  Jean C. Lee,et al.  Vaccination and passive immunisation against Staphylococcus aureus. , 2008, International journal of antimicrobial agents.

[16]  V. Nizet,et al.  Recent advances in understanding the molecular basis of group B Streptococcus virulence , 2008, Expert Reviews in Molecular Medicine.

[17]  C. Arrecubieta,et al.  Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice. , 2008, The Journal of infectious diseases.

[18]  J. Middleton Staphylococcus aureus antigens and challenges in vaccine development , 2008, Expert review of vaccines.

[19]  O. Schneewind,et al.  Vaccine protection against Staphylococcus aureus pneumonia , 2008, The Journal of experimental medicine.

[20]  R. Lynfield,et al.  The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  C. Woods,et al.  Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-Staphylococcus aureus Capsular Polysaccharide Immune Globulin in Treatment of Staphylococcus aureus Bacteremia , 2007, Antimicrobial Agents and Chemotherapy.

[22]  Phalla Ou,et al.  Prevalence of rheumatic heart disease detected by echocardiographic screening. , 2007, The New England journal of medicine.

[23]  Mengyao Liu,et al.  Active and Passive Immunizations with the Streptococcal Esterase Sse Protect Mice against Subcutaneous Infection with Group A Streptococci , 2007, Infection and Immunity.

[24]  L. Madoff,et al.  Recombinant Group B Streptococcus Beta C Protein and a Variant with the Deletion of Its Immunoglobulin A-Binding Site Are Protective Mouse Maternal Vaccines and Effective Carriers in Conjugate Vaccines , 2007, Infection and Immunity.

[25]  L. Paoletti,et al.  Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. , 2007, Vaccine.

[26]  C. Rizzo,et al.  Efficacy of autovaccination therapy on post-coronary artery bypass grafting methicillin-resistant Staphylococcus aureus mediastinitis. , 2006, Interactive cardiovascular and thoracic surgery.

[27]  R. Rappuoli,et al.  Group B Streptococcus: global incidence and vaccine development , 2006, Nature Reviews Microbiology.

[28]  O. Schneewind,et al.  Vaccine assembly from surface proteins of Staphylococcus aureus , 2006, Proceedings of the National Academy of Sciences.

[29]  K. Omoe,et al.  Intranasal vaccination with a double mutant of staphylococcal enterotoxin C provides protection against Staphylococcus aureus infection. , 2006, Microbes and infection.

[30]  A. Potter,et al.  DNA-protein immunization against the GapB and GapC proteins of a mastitis isolate of Staphylococcus aureus. , 2006, Veterinary immunology and immunopathology.

[31]  V. Fowler,et al.  Phase II, Randomized, Double-Blind, Multicenter Study Comparing the Safety and Pharmacokinetics of Tefibazumab to Placebo for Treatment of Staphylococcus aureus Bacteremia , 2006, Antimicrobial Agents and Chemotherapy.

[32]  I. Margarit,et al.  Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease. , 2006, The Journal of infectious diseases.

[33]  M. S. Barbagelata,et al.  Attenuation and Persistence of and Ability To Induce Protective Immunity to a Staphylococcus aureus aroA Mutant in Mice , 2006, Infection and Immunity.

[34]  S. Foster,et al.  Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. , 2006, The Journal of infectious diseases.

[35]  Charles Y. Tan,et al.  A Novel Staphylococcus aureus Vaccine: Iron Surface Determinant B Induces Rapid Antibody Responses in Rhesus Macaques and Specific Increased Survival in a Murine S. aureus Sepsis Model , 2006, Infection and Immunity.

[36]  B. Shen,et al.  A novel peptide isolated from phage library to substitute a complex system for a vaccine against staphylococci infection. , 2006, Vaccine.

[37]  H. Courtney,et al.  Anti‐phagocytic mechanisms of Streptococcus pyogenes: binding of fibrinogen to M‐related protein , 2006, Molecular microbiology.

[38]  S. Black,et al.  Prospects for active and passive immunization against Staphylococcus aureus. , 2006, The Pediatric infectious disease journal.

[39]  G. Bensi,et al.  Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome , 2006, Nature Biotechnology.

[40]  Fredric Carlsson,et al.  Binding of human plasma proteins to Streptococcus pyogenes M protein determines the location of opsonic and non‐opsonic epitopes , 2006, Molecular microbiology.

[41]  J. Carapetis,et al.  The global burden of group A streptococcal diseases. , 2005, The Lancet. Infectious diseases.

[42]  A. Bisno,et al.  Prospects for a group A streptococcal vaccine: rationale, feasibility, and obstacles--report of a National Institute of Allergy and Infectious Diseases workshop. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  J. Langley,et al.  Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteers. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  G. Bensi,et al.  Group A Streptococcus produce pilus-like structures containing protective antigens and Lancefield T antigens , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  S. Black,et al.  Prevention of Staphylococcus aureus infections: advances in vaccine development , 2005, Expert review of vaccines.

[46]  Jaideep P. Sundaram,et al.  Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome". , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  E. Gorovits,et al.  Characterization of a Humanized Monoclonal Antibody Recognizing Clumping Factor A Expressed by Staphylococcus aureus , 2005, Infection and Immunity.

[48]  A. Nakane,et al.  Immunization with glutathione S-transferase and mutant toxic shock syndrome toxin 1 fusion protein protects against Staphylococcus aureus infection. , 2005, FEMS immunology and medical microbiology.

[49]  H. Tettelin,et al.  Identification of a Universal Group B Streptococcus Vaccine by Multiple Genome Screen , 2005, Science.

[50]  Bart J. Currie,et al.  Surface Analyses and Immune Reactivities of Major Cell Wall-Associated Proteins of Group A Streptococcus , 2005, Infection and Immunity.

[51]  Kevin F. Jones,et al.  Clinical and Microbiological Responses of Volunteers to Combined Intranasal and Oral Inoculation with a Streptococcus gordonii Carrier Strain Intended for Future Use as a Group A Streptococcus Vaccine , 2005, Infection and Immunity.

[52]  R. Feldman,et al.  Vaccination against Group B streptococcus , 2005, Expert review of vaccines.

[53]  A. Fattom,et al.  Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients. , 2004, Vaccine.

[54]  S. Olmsted,et al.  Immunization with C5a peptidase from either group A or B streptococci enhances clearance of group A streptococci from intranasally infected mice. , 2004, Vaccine.

[55]  James D. Campbell,et al.  Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial. , 2004, JAMA.

[56]  M. Pichichero Group A streptococcal vaccines. , 2004, JAMA.

[57]  C. Baker,et al.  Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. , 2004, The Journal of infectious diseases.

[58]  L. Weisman Coagulase-negative staphylococcal disease: emerging therapies for the neonatal and pediatric patient , 2004, Current opinion in infectious diseases.

[59]  A. Potter,et al.  Characterization of two proteins of Staphylococcus aureus isolated from bovine clinical mastitis with homology to glyceraldehyde-3-phosphate dehydrogenase. , 2004, Veterinary microbiology.

[60]  A. Fattom,et al.  Staphylococcus aureus types 5 and 8 capsular polysaccharide-protein conjugate vaccines. , 2004, American heart journal.

[61]  D. Kasper,et al.  Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. , 2004, The Journal of infectious diseases.

[62]  M. Höök,et al.  MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection. , 2004, Current opinion in drug discovery & development.

[63]  A. Fattom,et al.  Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. , 2004, Vaccine.

[64]  G. Lindahl,et al.  Intranasal Immunization of Mice with Group B Streptococcal Protein Rib and Cholera Toxin B Subunit Confers Protection against Lethal Infection , 2004, Infection and Immunity.

[65]  K. O'Riordan,et al.  Staphylococcus aureus Capsular Polysaccharides , 2004, Clinical Microbiology Reviews.

[66]  H. Courtney,et al.  Serum Opacity Factor (SOF) of Streptococcus pyogenes Evokes Antibodies That Opsonize Homologous and Heterologous SOF-Positive Serotypes of Group A Streptococci , 2003, Infection and Immunity.

[67]  D. Kasper,et al.  Glycoconjugate vaccines to prevent group B streptococcal infections , 2003, Expert opinion on biological therapy.

[68]  K. Omoe,et al.  Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. , 2003, The Journal of infectious diseases.

[69]  C. Baker,et al.  Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. , 2003, Vaccine.

[70]  D. Kasper,et al.  Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. , 2003, The Journal of infectious diseases.

[71]  D. Santos,et al.  Protective immune response against methicillin resistant Staphylococcus aureus in a murine model using a DNA vaccine approach. , 2003, Vaccine.

[72]  M. Davies,et al.  Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection. , 2003, The Journal of infectious diseases.

[73]  Dwight R. Johnson,et al.  Epidemiologic Analysis of Invasive and Noninvasive Group A Streptococcal Isolates in Hong Kong , 2003, Journal of Clinical Microbiology.

[74]  S. Olmsted,et al.  Immunization with C5a Peptidase or Peptidase-Type III Polysaccharide Conjugate Vaccines Enhances Clearance of Group B Streptococci from Lungs of Infected Mice , 2002, Infection and Immunity.

[75]  Ian T. Paulsen,et al.  Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[76]  L. Madoff,et al.  Vaccines to prevent neonatal GBS infection. , 2002, Seminars in neonatology : SN.

[77]  S. Bavari,et al.  Protection against Bacterial Superantigen Staphylococcal Enterotoxin B by Passive Vaccination , 2002, Infection and Immunity.

[78]  M. Reddish,et al.  Immunogenicity of a 26-Valent Group A Streptococcal Vaccine , 2002, Infection and Immunity.

[79]  S. Black,et al.  Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. , 2002, The New England journal of medicine.

[80]  T. Foster,et al.  Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. , 2001, The Journal of infectious diseases.

[81]  Y. Li,et al.  Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat. , 2001, Vaccine.

[82]  L. Paoletti Potency of clinical group B streptococcal conjugate vaccines. , 2001, Vaccine.

[83]  S. Hamada,et al.  Systemic and Mucosal Immunizations with Fibronectin-Binding Protein FBP54 Induce Protective Immune Responses against Streptococcus pyogenes Challenge in Mice , 2001, Infection and Immunity.

[84]  D. Ohlendorf,et al.  Toxoids of Streptococcal Pyrogenic Exotoxin A Are Protective in Rabbit Models of Streptococcal Toxic Shock Syndrome , 2000, Infection and Immunity.

[85]  M. Cunningham,et al.  Pathogenesis of group A streptococcal infections. , 2000, Clinical microbiology reviews.

[86]  C. Chapman,et al.  Identification of an Immunodominant ABC Transporter in Methicillin-Resistant Staphylococcus aureusInfections , 2000, Infection and Immunity.

[87]  G. S. Chhatwal,et al.  Protective immune response against Streptococcus pyogenes in mice after intranasal vaccination with the fibronectin-binding protein SfbI. , 1999, The Journal of infectious diseases.

[88]  A. Conde Staphylococcus aureus infections. , 1998, The New England journal of medicine.

[89]  A. Tarkowski,et al.  Vaccination with a recombinant fragment of collagen adhesin provides protection against Staphylococcus aureus-mediated septic death. , 1998, The Journal of clinical investigation.

[90]  R. Rasooly,et al.  Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. , 1998, Science.

[91]  M. Good,et al.  Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus. , 1997, International immunology.

[92]  A. Fattom,et al.  Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats , 1997, Infection and immunity.

[93]  P. Cleary,et al.  Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by the group A Streptococcus , 1997, Infection and immunity.

[94]  D. Kasper,et al.  Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. , 1996, The Journal of clinical investigation.

[95]  W. Baze,et al.  Immunogenicity and efficacy against lethal aerosol staphylococcal enterotoxin B challenge in monkeys by intramuscular and respiratory delivery of proteosome-toxoid vaccines , 1996, Infection and immunity.

[96]  D. Kernodle,et al.  Passive immunization with antiserum to a nontoxic alpha-toxin mutant from Staphylococcus aureus is protective in a murine model , 1996, Infection and immunity.

[97]  J. Sarwar,et al.  A Staphylococcus aureus capsular polysaccharide (CP) vaccine and CP-specific antibodies protect mice against bacterial challenge , 1996, Infection and immunity.

[98]  J. C. Lee,et al.  The prospects for developing a vaccine against Staphylococcus aureus. , 1996, Trends in microbiology.

[99]  J. C. Lee,et al.  Antibodies to capsular polysaccharides are not protective against experimental Staphylococcus aureus endocarditis , 1995, Infection and immunity.

[100]  J. Musser,et al.  Vaccination with streptococcal extracellular cysteine protease (interleukin-1 beta convertase) protects mice against challenge with heterologous group A streptococci. , 1994, Microbial pathogenesis.

[101]  G. Lindahl,et al.  Protein rib: a novel group B streptococcal cell surface protein that confers protective immunity and is expressed by most strains causing invasive infections , 1993, The Journal of experimental medicine.

[102]  I. Pastan,et al.  Laboratory and clinical evaluation of conjugate vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides bound to Pseudomonas aeruginosa recombinant exoprotein A , 1993, Infection and immunity.

[103]  D. Kasper,et al.  Protection of neonatal mice from group B streptococcal infection by maternal immunization with beta C protein , 1992, Infection and immunity.

[104]  M. Bronze,et al.  Epitopes of group A streptococcal M protein that evoke cross-protective local immune responses. , 1992, Journal of immunology.

[105]  V. Fischetti,et al.  Synthetic peptide vaccine against mucosal colonization by group A streptococci. I. Protection against a heterologous M serotype with shared C repeat region epitopes. , 1990, Journal of immunology.

[106]  E. Beachey,et al.  Protective immunity evoked by locally administered group A streptococcal vaccines in mice. , 1988, Journal of immunology.

[107]  V. Fischetti,et al.  Influence of intranasal immunization with synthetic peptides corresponding to conserved epitopes of M protein on mucosal colonization by group A streptococci , 1988, Infection and immunity.

[108]  D. Greenberg,et al.  Influence of Staphylococcus aureus antibody on experimental endocarditis in rabbits , 1987, Infection and immunity.

[109]  R. H. Johnson,et al.  Human immune response to immunization with a structurally defined polypeptide fragment of streptococcal M protein , 1979, The Journal of experimental medicine.

[110]  C. Adlam,et al.  Effect immunization with highly purified alpha- and beta-toxins on staphylococcal mastitis in rabbits , 1977, Infection and immunity.

[111]  D. Kasper,et al.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. , 1976, The New England journal of medicine.

[112]  E. N. Fox,et al.  Protective studies with a group A streptococcal M protein vaccine. II. Challange of volenteers after local immunization in the upper respiratory tract. , 1975, The Journal of infectious diseases.

[113]  E. N. Fox,et al.  Protective study with a group A streptococcal M protein vaccine. Infectivity challenge of human volunteers. , 1973, The Journal of clinical investigation.

[114]  R. Lancefield Current knowledge of type-specific M antigens of group A streptococci. , 1962, Journal of immunology.

[115]  H. Swift,et al.  INTRAVENOUS VACCINATION WITH HEMOLYTIC STREPTOCOCCI: ITS INFLUENCE ON THE INCIDENCE OF RECURRENCE OF RHEUMATIC FEVER IN CHILDREN , 1931 .

[116]  A. R. Dochez,et al.  STUDIES ON THE BIOLOGY OF STREPTOCOCCUS , 1926, The Journal of experimental medicine.

[117]  O. Avery,et al.  STUDIES ON THE BIOLOGY OF STREPTOCOCCUS , 1919, The Journal of experimental medicine.

[118]  I. Margarit,et al.  Preventing bacterial infections with pilus-based vaccines: the group B streptococcus paradigm. , 2009, The Journal of infectious diseases.

[119]  W. Benitz Epidemiology of Invasive Group B Streptococcal Disease in the United States, 1999-2005 , 2009 .

[120]  D. Santillan,et al.  Protective immunization in mice against group B streptococci using encapsulated C5a peptidase. , 2008, American journal of obstetrics and gynecology.

[121]  J. Dale Current status of group A streptococcal vaccine development. , 2008, Advances in experimental medicine and biology.

[122]  L. Weisman Antibody for the prevention of neonatal noscocomial staphylococcal infection: a review of the literature. , 2007, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[123]  J. Zabriskie,et al.  Group A streptococcus (GAS) carbohydrate as an immunogen for protection against GAS infection. , 2006, The Journal of infectious diseases.

[124]  J. Musser,et al.  Identification of new candidate vaccine antigens made by Streptococcus pyogenes: purification and characterization of 16 putative extracellular lipoproteins. , 2004, The Journal of infectious diseases.

[125]  Rino Rappuoli,et al.  Reverse vaccinology. , 2000, Current opinion in microbiology.

[126]  J. Dale Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments. , 1999, Vaccine.

[127]  J. Zabriskie,et al.  Phagocytic, serological, and protective properties of streptococcal group A carbohydrate antibodies. , 1997, Advances in experimental medicine and biology.

[128]  M. Farley Group B streptococcal infection in older patients. Spectrum of disease and management strategies. , 1995, Drugs & aging.

[129]  A. Schuchat,et al.  Epidemiology of group B streptococcal disease. Risk factors, prevention strategies, and vaccine development. , 1994, Epidemiologic reviews.

[130]  D. Watson Staphylococcal mastitis vaccine. , 1992, Vaccine.

[131]  L. Poole-Warren,et al.  Vaccination for prevention of CAPD associated staphylococcal infection: results of a prospective multicentre clinical trial. , 1991, Clinical nephrology.